June 8, 2016
Kyowa Hakko Kirin said on June 6 that it has agreed with US-based Medgenics to codevelop its anti-LIGHT monoclonal antibody for the treatment of severe pediatric onset inflammatory bowel disease (IBD). The PII-ready antibody binds to the pro-inflammatory cytokine called...read more